Bafna [BAFNAPH] vs Suven Life Sciences [SUVEN] Detailed Stock Comparison
Bafna
NSE
Loading...
Suven Life Sciences
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Bafna wins in 11 metrics, Suven Life Sciences wins in 7 metrics, with 0 ties. Bafna appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bafna | Suven Life Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 48.36 | -28.31 | Suven Life Sciences |
| Price-to-Book Ratio | 4.76 | 41.36 | Bafna |
| Debt-to-Equity Ratio | 33.25 | 0.00 | Suven Life Sciences |
| PEG Ratio | -0.09 | -0.34 | Suven Life Sciences |
| EV/EBITDA | 28.24 | -24.12 | Suven Life Sciences |
| Profit Margin (TTM) | 5.62% | 84.44% | Suven Life Sciences |
| Operating Margin (TTM) | 10.68% | -2,791.92% | Bafna |
| EBITDA Margin (TTM) | 10.68% | N/A | N/A |
| Return on Equity | 4.90% | -146.15% | Bafna |
| Return on Assets (TTM) | 2.71% | -118.91% | Bafna |
| Free Cash Flow (TTM) | $2.76M | $-1.91B | Bafna |
| 1-Year Return | 117.84% | 49.21% | Bafna |
| Price-to-Sales Ratio (TTM) | 2.72 | 632.35 | Bafna |
| Enterprise Value | $4.26B | $44.90B | Suven Life Sciences |
| EV/Revenue Ratio | 2.89 | 597.31 | Bafna |
| Gross Profit Margin (TTM) | 35.25% | 100.00% | Suven Life Sciences |
| Revenue per Share (TTM) | $62 | $0 | Bafna |
| Earnings per Share (Diluted) | $3.50 | $-8.45 | Bafna |
| Beta (Stock Volatility) | 0.66 | 0.78 | Bafna |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Bafna vs Suven Life Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bafna | -2.00% | -0.09% | 74.31% | 97.96% | 139.78% | 108.60% |
| Suven Life Sciences | -2.18% | 3.79% | -10.27% | -21.82% | 76.25% | 63.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bafna | 117.84% | 68.68% | 143.15% | 344.95% | 269.68% | 269.68% |
| Suven Life Sciences | 49.21% | 215.69% | 329.98% | -26.12% | 600.33% | 3,806.72% |
News Based Sentiment: Bafna vs Suven Life Sciences
Bafna
News based Sentiment: POSITIVE
Despite a 2% share price decline on October 1st, Bafna Pharmaceuticals has demonstrated substantial growth over the past six months (130.9%) and year (20.99%). This positive trend outweighs the short-term fluctuation, indicating a generally positive investment story for the month.
Suven Life Sciences
News based Sentiment: MIXED
October was a month of conflicting signals for Suven Life Sciences. While the company benefited from a positive pharmaceutical sector rally and maintained a debt-free status, it also reported continued quarterly losses and received a negative analyst rating. This creates a complex investment narrative with both potential opportunities and significant risks.
Performance & Financial Health Analysis: Bafna vs Suven Life Sciences
| Metric | BAFNAPH | SUVEN |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.16B | ₹47.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 34,831 | 184,111 |
| 90 Day Avg. Volume | 27,820 | 150,383 |
| Last Close | ₹169.18 | ₹204.83 |
| 52 Week Range | ₹69.00 - ₹176.33 | ₹102.50 - ₹299.99 |
| % from 52W High | -4.05% | -31.72% |
| All-Time High | ₹233.55 (Dec 14, 2020) | ₹338.50 (Apr 13, 2015) |
| % from All-Time High | -27.56% | -39.49% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.86% |
| Quarterly Earnings Growth | 0.04% | 0.86% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.84% |
| Operating Margin (TTM) | 0.11% | -27.92% |
| Return on Equity (TTM) | 0.05% | -1.46% |
| Debt to Equity (MRQ) | 33.25 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹35.58 | ₹5.04 |
| Cash per Share (MRQ) | ₹1.45 | ₹2.75 |
| Operating Cash Flow (TTM) | ₹207.66M | ₹-1,590,282,000 |
| Levered Free Cash Flow (TTM) | ₹41.53M | ₹-1,607,450,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Bafna vs Suven Life Sciences
| Metric | BAFNAPH | SUVEN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 48.36 | -28.31 |
| Forward P/E | N/A | 10.78 |
| PEG Ratio | -0.09 | -0.34 |
| Price to Sales (TTM) | 2.72 | 632.35 |
| Price to Book (MRQ) | 4.76 | 41.36 |
| Market Capitalization | ||
| Market Capitalization | ₹4.16B | ₹47.99B |
| Enterprise Value | ₹4.26B | ₹44.90B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.89 | 597.31 |
| Enterprise to EBITDA | 28.24 | -24.12 |
| Risk & Other Metrics | ||
| Beta | 0.66 | 0.78 |
| Book Value per Share (MRQ) | ₹35.58 | ₹5.04 |
Financial Statements Comparison: Bafna vs Suven Life Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BAFNAPH | SUVEN |
|---|---|---|
| Revenue/Sales | ₹346.24M | ₹18.67M |
| Cost of Goods Sold | ₹224.18M | ₹0 |
| Gross Profit | ₹122.06M | ₹18.67M |
| Research & Development | N/A | ₹414.88M |
| Operating Income (EBIT) | ₹36.99M | ₹-521.17M |
| EBITDA | ₹56.64M | ₹-501.49M |
| Pre-Tax Income | ₹33.89M | ₹-515.17M |
| Income Tax | ₹0 | ₹0 |
| Net Income (Profit) | ₹33.89M | ₹-515.17M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BAFNAPH | SUVEN |
|---|---|---|
| Cash & Equivalents | ₹34.33M | ₹150.26M |
| Total Current Assets | ₹847.28M | ₹754.72M |
| Total Current Liabilities | ₹518.52M | ₹234.86M |
| Long-Term Debt | ₹140.29M | N/A |
| Total Shareholders Equity | ₹848.07M | ₹1.10B |
| Retained Earnings | ₹-431.31M | ₹-6.01B |
| Property, Plant & Equipment | ₹192.19M | ₹756.69M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BAFNAPH | SUVEN |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BAFNAPH | SUVEN |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 34,831 | 184,111 |
| Average Daily Volume (90 Day) | 27,820 | 150,383 |
| Shares Outstanding | 23.66M | 218.07M |
| Float Shares | 4.55M | 67.61M |
| % Held by Insiders | 0.89% | 0.69% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Bafna vs Suven Life Sciences
| Metric | BAFNAPH | SUVEN |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |